scispace - formally typeset
D

Diederick E. Grobbee

Researcher at Utrecht University

Publications -  1108
Citations -  136069

Diederick E. Grobbee is an academic researcher from Utrecht University. The author has contributed to research in topics: Population & Risk factor. The author has an hindex of 155, co-authored 1051 publications receiving 122748 citations. Previous affiliations of Diederick E. Grobbee include National Heart Foundation of Australia & Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal ArticleDOI

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.

TL;DR: The effect of postponing prophylaxis on long-term arthropathy was studied in a cohort of 76 patients with severe hemophilia born between 1965 and 1985, finding that most patients have their first joint bleed after the age of 2 years.
Journal ArticleDOI

Plasma Total Homocysteine, B Vitamins, and Risk of Coronary Atherosclerosis

TL;DR: The data show a positive association between plasma tHcy and risk of severe coronary atherosclerosis, of similar strength for fasting and postload tH Cy levels, and suggest that the association exists over a wide range of tHCy levels, without a clear cutoff point below which there is no increased risk.
Journal ArticleDOI

Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders : Results From a Randomized, Double-Blind, Placebo-Controlled Trial

TL;DR: Aspirin given as adjuvant therapy to regular antipsychotic treatment reduces the symptoms of schizophrenia spectrum disorders, and is more pronounced in those with the more altered immune function.
Journal ArticleDOI

Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population Relation to Cardiovascular Risk Factors and Disease

TL;DR: High fasting serum free IGF-I levels are associated with a decreased presence of atherosclerotic plaques and coronary artery disease and lower serum triglycerides, whereas high fasting IGFBP-1 levels areassociated with a more favorable cardiovascular risk profile.
Journal Article

The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort

TL;DR: From results, it is suggested that when the use of VPA during pregnancy cannot be avoided, the teratogenic risk might be diminished by reduction of the daily dose.